Orange Book product · Generic (ANDA)
SUCRALFATE
SUCRALFATE
At a glance
Mar 15, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 15, 2022
4 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
SUCRALFATE
Strength
1GM/10ML
Dosage form
SUSPENSION
Route
ORAL
TE code
AB
Application
ANDA 211884
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of SUCRALFATE
- 1993CARAFATEBrand (NDA)
NDA 019183 · ABBVIE
- —CARAFATEBrand (NDA)
NDA 018333 · ABBVIE
- 2026SUCRALFATEGeneric (ANDA)
ANDA 212141 · GLENMARK PHARMS LTD
- 2025SUCRALFATEGeneric (ANDA)
ANDA 211780 · PADAGIS US
- 2024SUCRALFATEGeneric (ANDA)
ANDA 217126 · COSETTE PHARMS NC
- 2024SUCRALFATEGeneric (ANDA)
ANDA 212769 · HIKMA
- 2024SUCRALFATEGeneric (ANDA)
ANDA 216474 · STRIDES PHARMA
- 2024SUCRALFATEGeneric (ANDA)
ANDA 216726 · ABON PHARMS LLC
- 2024SUCRALFATEGeneric (ANDA)
ANDA 213549 · PD PARTNERS
- 2023SUCRALFATEGeneric (ANDA)
ANDA 215705 · ZYDUS LIFESCIENCES
- 2022SUCRALFATEGeneric (ANDA)
ANDA 212913 · MYLAN
- 2022SUCRALFATEGeneric (ANDA)
ANDA 215576 · AMNEAL PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
